Grade IV glioma patients with IDH1 mutation had a median overall survival of 46.9 (95% CI: 38.2–55.5) months compared to 50.2 (95% CI: 46.5–53.9) months for those who tested negative (p = 0.22). The gene discussed is IDH1; the disease is glioma.